Annual FCF
-$20.48 M
-$1.13 M-5.82%
31 December 2023
Summary:
Brainstorm Cell Therapeutics annual free cash flow is currently -$20.48 million, with the most recent change of -$1.13 million (-5.82%) on 31 December 2023. During the last 3 years, it has risen by +$15.10 million (+42.44%). BCLI annual FCF is now -292414.29% below its all-time high of -$7000.00, reached on 31 March 2003.BCLI Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$3.30 M
-$1.62 M-96.02%
30 September 2024
Summary:
Brainstorm Cell Therapeutics quarterly free cash flow is currently -$3.30 million, with the most recent change of -$1.62 million (-96.02%) on 30 September 2024. Over the past year, it has increased by +$3.13 million (+48.67%). BCLI quarterly FCF is now -187.81% below its all-time high of $3.76 million, reached on 30 September 2017.BCLI Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$11.33 M
+$3.13 M+21.64%
30 September 2024
Summary:
Brainstorm Cell Therapeutics TTM free cash flow is currently -$11.33 million, with the most recent change of +$3.13 million (+21.64%) on 30 September 2024. Over the past year, it has increased by +$10.51 million (+48.12%). BCLI TTM FCF is now -708025.00% below its all-time high of -$1600.00, reached on 30 June 2002.BCLI TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BCLI Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -5.8% | +48.7% | +48.1% |
| 3 y3 years | +42.4% | +50.7% | +60.8% |
| 5 y5 years | -60.5% | +11.5% | +5.0% |
BCLI Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -5.8% | +42.4% | -96.0% | +51.3% | at high | +60.8% |
| 5 y | 5 years | -74.7% | +42.4% | -96.0% | +78.1% | at high | +68.2% |
| alltime | all time | <-9999.0% | +42.4% | -187.8% | +78.1% | <-9999.0% | +68.2% |
Brainstorm Cell Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$3.30 M(+96.0%) | -$11.33 M(-21.6%) |
| June 2024 | - | -$1.68 M(-45.1%) | -$14.46 M(-26.1%) |
| Mar 2024 | - | -$3.06 M(-6.8%) | -$19.55 M(-4.5%) |
| Dec 2023 | -$20.48 M(+5.8%) | -$3.29 M(-48.9%) | -$20.48 M(-6.2%) |
| Sept 2023 | - | -$6.43 M(-5.2%) | -$21.84 M(+7.8%) |
| June 2023 | - | -$6.78 M(+70.0%) | -$20.26 M(+3.2%) |
| Mar 2023 | - | -$3.99 M(-14.2%) | -$19.64 M(+1.5%) |
| Dec 2022 | -$19.35 M(-27.2%) | -$4.65 M(-4.2%) | -$19.35 M(-4.4%) |
| Sept 2022 | - | -$4.85 M(-21.2%) | -$20.24 M(-8.4%) |
| June 2022 | - | -$6.15 M(+66.4%) | -$22.09 M(+3.7%) |
| Mar 2022 | - | -$3.70 M(-33.3%) | -$21.29 M(-19.9%) |
| Dec 2021 | -$26.59 M(-25.2%) | -$5.54 M(-17.2%) | -$26.59 M(-7.9%) |
| Sept 2021 | - | -$6.70 M(+25.0%) | -$28.86 M(-1.1%) |
| June 2021 | - | -$5.36 M(-40.5%) | -$29.18 M(-1.2%) |
| Mar 2021 | - | -$9.00 M(+15.2%) | -$29.53 M(-17.0%) |
| Dec 2020 | -$35.57 M(+203.5%) | -$7.81 M(+11.4%) | -$35.57 M(+13.3%) |
| Sept 2020 | - | -$7.01 M(+22.8%) | -$31.38 M(+11.7%) |
| June 2020 | - | -$5.71 M(-62.0%) | -$28.10 M(+8.4%) |
| Mar 2020 | - | -$15.04 M(+314.9%) | -$25.92 M(+121.1%) |
| Dec 2019 | -$11.72 M(-8.1%) | -$3.62 M(-2.8%) | -$11.72 M(-1.7%) |
| Sept 2019 | - | -$3.73 M(+5.6%) | -$11.93 M(-19.4%) |
| June 2019 | - | -$3.53 M(+320.6%) | -$14.79 M(+29.5%) |
| Mar 2019 | - | -$839.00 K(-78.1%) | -$11.43 M(-10.4%) |
| Dec 2018 | -$12.76 M(+401.5%) | -$3.83 M(-41.9%) | -$12.76 M(+7.0%) |
| Sept 2018 | - | -$6.59 M(+4021.9%) | -$11.92 M(+658.9%) |
| June 2018 | - | -$160.00 K(-92.6%) | -$1.57 M(-48.9%) |
| Mar 2018 | - | -$2.17 M(-27.6%) | -$3.07 M(+20.8%) |
| Dec 2017 | -$2.54 M(-57.3%) | -$3.00 M(-179.8%) | -$2.54 M(+239.2%) |
| Sept 2017 | - | $3.76 M(-326.1%) | -$750.00 K(-84.4%) |
| June 2017 | - | -$1.66 M(+1.2%) | -$4.79 M(+4.3%) |
| Mar 2017 | - | -$1.64 M(+36.5%) | -$4.60 M(-22.9%) |
| Dec 2016 | -$5.96 M(-20.0%) | -$1.20 M(+320.6%) | -$5.96 M(-1.7%) |
| Sept 2016 | - | -$286.00 K(-80.5%) | -$6.07 M(-27.1%) |
| June 2016 | - | -$1.47 M(-51.3%) | -$8.32 M(-2.4%) |
| Mar 2016 | - | -$3.01 M(+129.9%) | -$8.52 M(+14.4%) |
| Dec 2015 | -$7.45 M(+60.3%) | -$1.31 M(-48.5%) | -$7.45 M(-9.3%) |
| Sept 2015 | - | -$2.54 M(+52.6%) | -$8.22 M(+20.9%) |
| June 2015 | - | -$1.67 M(-14.0%) | -$6.80 M(+11.4%) |
| Mar 2015 | - | -$1.94 M(-6.6%) | -$6.10 M(+31.2%) |
| Dec 2014 | -$4.65 M(+11.7%) | -$2.07 M(+85.3%) | -$4.65 M(+10.9%) |
| Sept 2014 | - | -$1.12 M(+15.4%) | -$4.19 M(+9.8%) |
| June 2014 | - | -$970.00 K(+100.0%) | -$3.82 M(-3.5%) |
| Mar 2014 | - | -$485.00 K(-70.0%) | -$3.96 M(-4.9%) |
| Dec 2013 | -$4.16 M | -$1.62 M(+117.6%) | -$4.16 M(+27.9%) |
| Sept 2013 | - | -$744.00 K(-32.9%) | -$3.25 M(-9.6%) |
| June 2013 | - | -$1.11 M(+60.7%) | -$3.60 M(+23.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2013 | - | -$690.00 K(-3.0%) | -$2.92 M(-3.6%) |
| Dec 2012 | -$3.02 M(+33.2%) | -$711.00 K(-34.7%) | -$3.02 M(+8.2%) |
| Sept 2012 | - | -$1.09 M(+154.2%) | -$2.79 M(+7.3%) |
| June 2012 | - | -$428.00 K(-46.4%) | -$2.60 M(-12.5%) |
| Mar 2012 | - | -$798.00 K(+65.9%) | -$2.98 M(+31.1%) |
| Dec 2011 | -$2.27 M(+9.5%) | -$481.00 K(-46.4%) | -$2.27 M(-2.9%) |
| Sept 2011 | - | -$898.00 K(+12.3%) | -$2.34 M(+26.9%) |
| June 2011 | - | -$800.00 K(+769.6%) | -$1.84 M(+17.8%) |
| Mar 2011 | - | -$92.00 K(-83.2%) | -$1.56 M(-24.6%) |
| Dec 2010 | -$2.07 M(+178.8%) | -$549.00 K(+36.6%) | -$2.07 M(+13.0%) |
| Sept 2010 | - | -$402.00 K(-22.8%) | -$1.84 M(+11.5%) |
| June 2010 | - | -$521.00 K(-13.5%) | -$1.65 M(+39.1%) |
| Mar 2010 | - | -$602.00 K(+93.6%) | -$1.18 M(+59.1%) |
| Dec 2009 | -$744.00 K(-60.6%) | -$311.00 K(+46.0%) | -$744.00 K(+28.7%) |
| Sept 2009 | - | -$213.00 K(+267.2%) | -$578.00 K(-28.8%) |
| June 2009 | - | -$58.00 K(-64.2%) | -$812.00 K(-33.8%) |
| Mar 2009 | - | -$162.00 K(+11.7%) | -$1.23 M(-35.0%) |
| Dec 2008 | -$1.89 M(-11.0%) | -$145.00 K(-67.6%) | -$1.89 M(-15.3%) |
| Sept 2008 | - | -$447.00 K(-5.5%) | -$2.23 M(-21.1%) |
| June 2008 | - | -$473.00 K(-42.5%) | -$2.83 M(+6.3%) |
| Mar 2008 | - | -$823.00 K(+69.0%) | -$2.66 M(+25.3%) |
| Dec 2007 | -$2.12 M(+113.0%) | -$487.00 K(-53.3%) | -$2.12 M(+29.8%) |
| Sept 2007 | - | -$1.04 M(+241.3%) | -$1.63 M(+52.6%) |
| June 2007 | - | -$305.60 K(+7.1%) | -$1.07 M(-9.4%) |
| Mar 2007 | - | -$285.40 K(-40.5%) | -$1.18 M(-28.7%) |
| Dec 2006 | -$996.00 K(-31.9%) | - | - |
| Sept 2006 | - | -$479.80 K(+15.3%) | -$1.66 M(+10.0%) |
| June 2006 | - | -$416.20 K(0.0%) | -$1.51 M(+3.0%) |
| Mar 2006 | - | -$416.20 K(+20.6%) | -$1.46 M(-0.6%) |
| Mar 2006 | -$1.46 M(+61.3%) | - | - |
| Dec 2005 | - | -$345.10 K(+5.1%) | -$1.47 M(-8.7%) |
| Sept 2005 | - | -$328.50 K(-11.7%) | -$1.61 M(+25.1%) |
| June 2005 | - | -$372.10 K(-12.4%) | -$1.29 M(+42.1%) |
| Mar 2005 | -$906.40 K(+5785.7%) | -$424.70 K(-12.6%) | -$906.40 K(+85.5%) |
| Dec 2004 | - | -$485.80 K(+8575.0%) | -$488.70 K(+6165.4%) |
| Sept 2004 | - | -$5600.00(-157.7%) | -$7800.00(+44.4%) |
| June 2004 | - | $9700.00(-238.6%) | -$5400.00(-65.2%) |
| Mar 2004 | -$15.40 K(+120.0%) | -$7000.00(+42.9%) | -$15.50 K(+59.8%) |
| Dec 2003 | - | -$4900.00(+53.1%) | -$9700.00(+115.6%) |
| Sept 2003 | - | -$3200.00(+700.0%) | -$4500.00(-22.4%) |
| June 2003 | - | -$400.00(-66.7%) | -$5800.00(-17.1%) |
| Mar 2003 | -$7000.00(-5.4%) | -$1200.00(-500.0%) | -$7000.00(+20.7%) |
| Dec 2002 | - | $300.00(-106.7%) | -$5800.00(-4.9%) |
| Sept 2002 | - | -$4500.00(+181.3%) | -$6100.00(+281.3%) |
| June 2002 | - | -$1600.00 | -$1600.00 |
| Mar 2002 | -$7400.00 | - | - |
FAQ
- What is Brainstorm Cell Therapeutics annual free cash flow?
- What is the all time high annual FCF for Brainstorm Cell Therapeutics?
- What is Brainstorm Cell Therapeutics annual FCF year-on-year change?
- What is Brainstorm Cell Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Brainstorm Cell Therapeutics?
- What is Brainstorm Cell Therapeutics quarterly FCF year-on-year change?
- What is Brainstorm Cell Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Brainstorm Cell Therapeutics?
- What is Brainstorm Cell Therapeutics TTM FCF year-on-year change?
What is Brainstorm Cell Therapeutics annual free cash flow?
The current annual FCF of BCLI is -$20.48 M
What is the all time high annual FCF for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics all-time high annual free cash flow is -$7000.00
What is Brainstorm Cell Therapeutics annual FCF year-on-year change?
Over the past year, BCLI annual free cash flow has changed by -$1.13 M (-5.82%)
What is Brainstorm Cell Therapeutics quarterly free cash flow?
The current quarterly FCF of BCLI is -$3.30 M
What is the all time high quarterly FCF for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics all-time high quarterly free cash flow is $3.76 M
What is Brainstorm Cell Therapeutics quarterly FCF year-on-year change?
Over the past year, BCLI quarterly free cash flow has changed by +$3.13 M (+48.67%)
What is Brainstorm Cell Therapeutics TTM free cash flow?
The current TTM FCF of BCLI is -$11.33 M
What is the all time high TTM FCF for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics all-time high TTM free cash flow is -$1600.00
What is Brainstorm Cell Therapeutics TTM FCF year-on-year change?
Over the past year, BCLI TTM free cash flow has changed by +$10.51 M (+48.12%)